Jane S. Ricciuti, RPh, MS


April 07, 2005

In This Article


The US Food and Drug Administration (FDA) has approved labeling changes for Crestor (rosuvastatin) based on postmarketing studies in Asian-Americans that highlight important information on the safe use of rosuvastatin to reduce the risk for serious muscle toxicity (myopathy/rhabdomyolysis), especially at the highest approved dose of 40 mg.

The FDA has granted approval of a new indication for Temodar (temozolomide) to be used concurrently with radiotherapy and as maintenance therapy after radiotherapy. Temozolomide can extend the lives of adult patients newly diagnosed with glioblastoma multiforme, the most common form of malignant brain cancer.

Antidiabetic Agents

  • Symlin (pramlintide) Injection

Antihypertensive Agents

  • Atacand (candesartan cilexetil) Tablets

Antilipemic Agents

  • Crestor (rosuvastatin) Tablets

Antineoplastic Agents

  • Temodar (temozolomide) Capsules

Antiviral Agents

  • Copegus (ribavirin) Tablets

Immunosuppressive Agents

  • Rapamune (sirolimus) Oral Solution and Tablets